Major pharmaceutical companies have expanded their production capacity, and the demand for pharmaceutical equipment may continue to increase

Since the beginning of this year, there have been reports of actions by pharmaceutical companies to expand production capacity
.
For example, Jiangxi Xinglin Baima Pharmaceutical Co.
, Ltd.
(referred to as "White Horse Pharmaceutical") has updated its prospectus recently and intends to sprint to the Growth Enterprise Market.
, R&D center construction project and marketing network construction project
.
Major pharmaceutical companies are expanding production capacity one after another (picture source: Pharmaceutical Network) On August 18, CDMO company Boton announced plans to acquire 70% of Yuyang Pharmaceutical for 171.
5 million yuan
.
Through this transaction, Proton will have three chemical raw material drug CDMO production bases in Chongqing Changshou, Jiangxi Yichun and Hubei Yingcheng, and the production capacity will be further expanded to 2000m3
.
On June 7, Hongri Pharmaceuticals held a groundbreaking ceremony for the intelligent manufacturing base of Chinese medicine formula granules with an investment of 750 million yuan, covering an area of ​​100 acres, and extracting 10,000 tons of Chinese medicinal materials per year in Shanghe County, Jinan City, Shandong Province
.
It is understood that after the Shandong base is completed, Hongri Pharmaceutical will produce 3,000 tons of traditional Chinese medicine formula granules annually, with an annual sales scale of about 3 billion yuan
.
In addition to the above companies, a number of domestic vaccine companies have also been actively deploying production capacity construction since 2021, including measures such as promoting the construction of their own factories to ensure vaccine production capacity and subsequent supply
.
In this regard, the analysis believes that a large number of pharmaceutical companies have expanded production capacity due to two main reasons
.
On the one hand, it is to advance the clinical pipeline, and on the other hand, it is also based on commercial considerations
.
With a series of medical reform policies promoting "quality improvement and cost reduction" as a major industry trend, companies wanting to improve their cost control capabilities are inseparable from large-scale production
.
Judging from the current industry development trend, it is expected that the expansion of production capacity of pharmaceutical companies will become the norm in the industry.
In the future, under the background of enterprise technological innovation and industrial upgrading, the development may accelerate
.
It is worth mentioning that the analysis predicts that the pharmaceutical equipment industry, which is the upstream of the pharmaceutical industry, will also have a lot to do in this process.

.
It is understood that some pharmaceutical equipment companies have pointed out in the 2020 performance report that with the expansion of downstream customers' high-end generic pharmaceutical companies' production capacity, the company's solid preparation and powder process project revenue will increase significantly in 2020, driving the company's performance to maintain steady growth
.
In order to seize the opportunity, it will also actively deploy in the field of powder processing equipment
.
It can be seen from the above that the expansion of the production capacity of pharmaceutical companies has played a great role in the performance of pharmaceutical equipment companies
.
The industry expects that as more and more pharmaceutical companies in the industry expand their production capacity, related companies will also welcome more benefits
.
In fact, a large number of pharmaceutical equipment companies have begun to take action to meet the production capacity needs of pharmaceutical companies
.
For example, in order to help pharmaceutical companies improve production efficiency and further ensure drug quality, many companies have developed numerous intelligent and fully automatic equipment and production lines, which have also been widely used in the pharmaceutical production process
.
Among them, some pharmaceutical companies have even begun to adopt the "machine substitution" model to achieve mechanized operations and continuously improve the quality of drug production, while also helping pharmaceutical companies reduce input costs
.
In general, judging from the current actions of a large number of pharmaceutical equipment companies, these companies have already made adequate preparations for the needs of pharmaceutical companies after they continue to expand their production capacity
.
However, it should be noted that while ushering in opportunities, we must also pay attention to the hidden problems
.
The industry believes that while gaining order growth, pharmaceutical machinery companies are also facing challenges such as possible restriction of their own production capacity and fierce market competition
.
Therefore, it is also necessary to continuously innovate and improve the technology and process of equipment, and to help the further development of pharmaceutical companies and themselves by creating higher-quality automated and intelligent equipment
.